SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010; 21: 194351.
  • 2
    Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis: a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 2011; 22: 153746.
  • 3
    Gold DT, Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep 2006; 4: 217.
  • 4
    Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122 Suppl :S3–13.
  • 5
    Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. The benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008; 23: 143541.
  • 6
    Hoer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 2009; 3: 2530.
  • 7
    Foster SA, Foley KA, Meadows ES, Johnston JA, Wang SS, Pohl GM, et al. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int 2011; 22: 5517.
  • 8
    Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115: 20916.
  • 9
    Office of the Surgeon General. Bone health and osteoporosis: a report of the Surgeon General. Rockville (MD): US Department of Health and Human Services; 2004.
  • 10
    Cheng H, Gary LC, Curtis JR, Saag KG, Kilgore ML, Morrisey MA, et al. Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data. Osteoporos Int 2009; 20: 150715.
  • 11
    Siris ES, Pasquale MK, Wang Y, Watts NB. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. J Bone Miner Res 2011; 26: 311.
  • 12
    Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009; 20: 212734.
  • 13
    Sheehy O, Kindundu CM, Barbeau M, LeLorier J. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 2009; 20: 136976.
  • 14
    Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008; 19: 8118.
  • 15
    Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 85661.
  • 16
    Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17: 164552.
  • 17
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 91520.
  • 18
    Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 447.
  • 19
    Shu AD, Stedman M, Polinski JM, Jan S, Patel M, Truppo C, et al. Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care 2009; 15: 41724.
  • 20
    Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 111723.
  • 21
    Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007; 92: 1296304.
  • 22
    Solomon DH, Gleeson T, Iversen M, Avorn J, Brookhart MA, Lii J, et al. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial. Osteoporos Int 2010; 21: 13744.
  • 23
    Vollmer W, Williams A, Vupputuri S, Rand C, Smith D, Feldstein A, et al. C-B4–03: promoting adherence to improve effectiveness of cardiovascular disease therapies (PATIENT): implementing a medication adherence intervention using health information technology. Clin Med Res 2011; 9: 152.
  • 24
    Vollmer W, Feldstein A, Smith D, Dubanoski J, Waterbury A, Schneider J, et al. Use of health information technology to improve medication adherence. Am J Manag Care 2011; 17: SP7987.
  • 25
    Choudhry NK, Fischer MA, Avorn J, Schneeweiss S, Solomon DH, Berman C, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood) 2010; 29: 19952001.
  • 26
    Lee YK, Nho JH, Ha YC, Koo KH. Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int 2011. E-pub ahead of print.